Edition:
India

People: Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

44.06USD
18 Apr 2019
Change (% chg)

$-0.87 (-1.94%)
Prev Close
$44.93
Open
$44.81
Day's High
$45.18
Day's Low
$42.48
Volume
342,387
Avg. Vol
168,653
52-wk High
$51.49
52-wk Low
$31.98

Dallas, Jayson 

Dr. Jayson Dallas, M.D., is an Independent Director of the Company. Dr. Dallas serves as the Chief Commercial Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc., a publicly held biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, since August 2015. Prior to Ultragenyx, Dr. Dallas served as General Manager of Roche, a healthcare company, in the United Kingdom from January 2013 to July 2015. Prior to this, he held two different positions at Genentech, a pharmaceutical company, as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology, from May 2010 to December 2012 in South San Francisco. Prior to joining Genentech, Dr. Dallas worked at Novartis and Pfizer / Pharmacia in the United States and previously at Roche in Switzerland. Dr. Dallas holds an M.D. from the University of the Witwatersrand, Johannesburg, South Africa and an M.B.A. from Ashridge Business School in the United Kingdom.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 268,250
Fiscal Year Total, USD 268,250

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Tina Nova

193,840

Amit Munshi

2,915,940

Kevin Lind

1,565,960

Steven Spector

1,599,320

Vincent Aurentz

1,612,650

Preston Klassen

1,787,280
As Of  31 Dec 2017